1. Pink Sheet
  2. >>Market Access

Part D Makes Payors Allies of Pharma Against Price Controls

 
• By Michael McCaughan

Medicare prescription drug plan sponsors don't want the government to take over the market any more than Big Pharma does. Can insurers and manufactuers work together to block interference in the new drug benefit?

Price controls are a threat to innovation. That has been the mantra of pharmaceutical companies in policy debates for a generation, though it hasn’t stopped some in Congress from advocating federal interventions in pricing.

But the refrain has been picked up in an unlikely quarter: by one of the largest pharmacy benefit management companies...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

‘Unprecedented Story’: Revoked EU Marketing Authorization Fails To Thwart Translarna Sales

 
• By Francesca Bruce

PTC Therapeutics is continuing to supply its Duchenne muscular dystrophy treatment, Translarna, in some European markets, despite EU revocation of the drug’s conditional marketing authorization earlier this year.

UK HRA Sets Targets For Digital Overhaul, Trial Transparency And Trust

 
• By Vibha Sharma

The UK Health Research Authority’s latest three-year strategy sets ambitious targets to make research more transparent. One World Health Organization official believes the authority can go further by setting equally high standards for the timely reporting of clinical trial results.

Valneva Expects UK And France to Lift Ixchiq Age Restriction Following EMA Decision

 
• By Anabel Costa-Ferreira

Other authorities are expected to mirror the European Medicines Agency’s decision to lift the temporary restriction it placed on using Valneva’s chikungunya vaccine in people aged 65 years and older.